Edarbi

Edarbi, the brand name for azilsartan medoxomil, is an angiotensin II receptor blocker (ARB) developed by Takeda Pharmaceuticals. Approved by the FDA in 2011, Edarbi is primarily used to treat high blood pressure (hypertension). Azilsartan medoxomil works by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict, resulting in the relaxation of blood vessels and a subsequent decrease in blood pressure. This helps reduce the risk of cardiovascular events such as stroke and heart attack. Edarbi is typically taken once daily in tablet form. Patients should adhere to their prescribed dosage and regularly consult their healthcare provider to monitor blood pressure and manage any potential side effects or interactions with other medications.